Expand all sections

Abnobaviscum 900

Extended indication Abnobaviscum 900 monotherapy for second line treatment of completely resected superficial intermedia
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Abnobaviscum 900
Domain Oncology
Reason of inclusion Generic
Main indication Bladder cancer
Extended indication Abnobaviscum 900 monotherapy for second line treatment of completely resected superficial intermediate-risk Bladder carcinoma in adults and elderly.
Route of administration Intravesical
Therapeutical formulation Infusion fluid
Budgetting framework Intermural (MSZ)
Additional remarks Abnobaviscum 900 enforces natural killer cell-mediated tumor cell lysis, reduces the migratory and invasive potential of tumor cells, and stimulates immune system cells both in vitro and in vivo.

Registration

Registration route Centralised (EMA)
ATMP No
Submission date March 2025
Expected Registration April 2026
Registration phase Clinical trials

Therapeutic value

Therapeutic value No estimate possible yet
Frequency of administration 1 times a month
References NCT02106572
Additional remarks Intravesical instillation of abnobaVISCUM 900 13 times during treatment period

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.